Recombinant Platform
RUCONEST® is a recombinant version of a human protein called C1 esterase inhibitor (C1INH). It is called recombinant because it is made outside the human body, in Baxalta Pharmaceutical Company’s proprietary technology platform.
RUCONEST® is a recombinant version of a human protein called C1 esterase inhibitor (C1INH). It is called recombinant because it is made outside the human body, in Baxalta Pharmaceutical Company’s proprietary technology platform.
Recombinant products are not made from blood plasma, this means patients treated with recombinant products are not at risk of blood borne pathogens.
The development of a recombinant therapeutic drug through to marketing approval by a regulatory authority is a lengthy process and starts by the generation and selection of a transgenic animal line. During this time, a research project must proceed through the early stages of genetic characterization of the transgenic animal line, as well as the recombinant protein produced in milk.
Several recombinant proteins are used for medical applications to help people with many diseases and medical needs. Recombinant medicines can be used in place of medicines made from human plasma.